Skip to content
Back to TPST

Tempest Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
2
Purchases
2
Sales
0
Purchase value
$500.00K
Sale value
$0.00

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Matthew AngelDirector · CEO and President · 10% owner
4
Filed Jun 23, 2026Period of report Mar 24, 20260001193125-26-279703
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 24, 2026
Common StockF2F1F3231,482$2.16$500.00K231,482IndirectBy Factor Bioscience Inc.
Filing footnotes · 5
  1. F1On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026.
  2. F2The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.
  3. F3The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.
  4. F4The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval.
  5. F5The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval.
Open on SEC EDGAR
Matthew AngelDirector · CEO and President · 10% owner
4
Filed Mar 25, 2026Period of report Mar 24, 20260001931356-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 24, 2026
Common StockF1231,482$2.16$500.00K231,482IndirectBy Factor Bioscience Inc.
Filing footnotes · 2
  1. F1The shares are held by Factor Bioscience Inc. ("Factor"). The Reporting Peron is the chief executive officer and chairman of the board of directors of Factor and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.
  2. F2The shares reported herein give effect to the pro rata distributions of shares by Erigen LLC for no additional consideration to its members, subsequent to the Reporting Person's last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distribution of such shares constituted only a change in the form the Reporting Person's ownership in such shares, the Reporting Person was not required to report the distribution pursuant to Section 16.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.